Action PRAX PRAXIS PRECISION MEDICINES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Praxis Precision Medicines, Inc.

Actions

PRAX

US74006W2070

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/04/2024 		Varia. 5j. Varia. 1 janv.
54,8 USD +3,63 % Graphique intraday de Praxis Precision Medicines, Inc. +16,87 % +145,96 %
08/04 PRAXIS PRECISION MEDICINES, INC. : Wedbush n'est pas inspiré par le dossier ZM
28/03 Praxis Precision Medicines fixe le prix de son offre publique de 200 millions de dollars MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Praxis Precision Medicines : April 2024 Corporate Presentation
PRAXIS PRECISION MEDICINES TO PRESENT ON ULIXACALTAMIDE AT THE AMERICAN ACADEMY OF NEUROLOGY 2024 ANNUAL MEETING
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
Certain Common Stock of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.
Certain Restricted Stock Units of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.
Certain Stock Options of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.
Praxis Precision Medicines to Participate in Upcoming April Conferences
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines Prices $200 Million Public Offering
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
Praxis Precision Medicines Plans Public Equity Offering
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response Achieving 100% Response in Treated Patients
Praxis Precision Medicines to Host PRAX-628 Program Update
Praxis Precision Medicines Files $750 Million Mixed-Securities Shelf Registration
Praxis Precision Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Praxis Precision Medicines : March 2024 Corporate Presentation
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Praxis Precision Medicines, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PRAX
  4. Actualités Praxis Precision Medicines, Inc.
  5. Autres langues